Latest Publication:

Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults
Research News

The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This was a Phase 1 randomized study to demonstrate the safety with promising results and can be read at the link below: 

Click here to read the full article
vaccine

Latest News

Lassa Virus under a microscope
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
An omicron COVID virus. A gray virus with red and orange projections.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
This is an HIV antibody with a yellow core and pink outer shell.
Targeting HIV broadly neutralizing antibody precursors with precision in humans.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…